UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File No. 001-40403 N2OFF, INC. (Exact name of registrant as specified in its charter) Nevada 26-4684680 (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File No. 001-40403 N2OFF, INC. (Exact name of registrant as specified in its charter) Nevada 26-4684680 (State or other jur ...

Financial Performance - Net cash used in operating activities was $8.0 million for the twelve months ended December 31, 2024, compared to $16.1 million for the same period of 2023, representing a 50.4% decrease[5] - Net loss for the three months and year ended December 31, 2024, was $3.0 million and $11.2 million, compared to $5.3 million and $22.6 million for the same period in 2023, showing a 43.4% and 50.5% reduction respectively[10] - General and administrative expenses for the three months and year ended December 31, 2024, were $0.9 million and $5.4 million, compared to $1.9 million and $6.7 million for the same period of the previous year, reflecting a 52.6% and 19.4% decrease respectively[7] - Research and development (R&D) expenses were $0.9 million and $6.7 million for the three months and year ended December 31, 2024, compared to $3.5 million and $19.2 million for the same period in 2023, indicating a 74.3% and 65.1% decrease respectively[6] Cash Position - As of December 31, 2024, pro forma cash and cash equivalents totaled $7.2 million, including $4.1 million of equity financing received after the end of the year[5] - The company estimates that its available cash will fund currently planned activities into the second quarter of 2025[5] Corporate Governance - The company appointed two new independent directors to its board on April 2, 2025, enhancing its governance structure[11] Strategic Development - The new oral formulation of plogosertib with improved bioavailability is under development[4] - The company has focused on the development of plogosertib, a PLK1 inhibitor for advanced cancers and hematological malignancies[4] Equity Impact - The deconsolidation of Cyclacel Limited is anticipated to increase stockholders' equity by approximately $5.0 million[4]

Exhibit 99.1 Cyclacel Pharmaceuticals, Inc. CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE BERKELEY HEIGHTS, NJ, April 2, 2025 - Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial results and provided a business update. "As part of Cyclacel's efforts to reduce operating costs, it has determined to focus on the developmen ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-41405 ALGORHYTHM HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

Financial Performance - Net sales decreased by $433,000 to $1,993,000 for the three-month period ended March 31, 2025, compared to $2,426,000 for the same period in 2024, primarily due to the loss of retail shelf space at two major customers[128] - Gross profit decreased to $500,000, or 25.1% of net sales, for the three-month period ended March 31, 2025, compared to $502,000, or 20.7% of net sales, for the same period in 2024[128] - Net loss available to common stockholders was $9,191,000, or $4.66 per share, for the three-month period ended March 31, 2025, compared to $2,367,000, or $73.76 per share, for the same period in 2024[129] - Total assets decreased from $18,302,000 at December 31, 2024, to $10,461,000 at March 31, 2025[129] Operating Expenses - Operating expenses increased by $521,000 to $3,310,000 for the three-month period ended March 31, 2025, primarily due to growth and development expenses for the SemiCab business[128] - Selling expenses increased by $134,000 to $764,000 for the three-month period ended March 31, 2025, compared to $630,000 for the same period in 2024, primarily due to increased online marketing and social media advertising campaigns[137] - General and administrative expenses rose by $387,000 to $2,546,000 for the three-month period ended March 31, 2025, from $2,159,000 in the same period of 2024, mainly due to expenses related to the development and growth of the SemiCab business[138] - Other expenses surged by $6,456,000 to $6,468,000 for the three-month period ended March 31, 2025, compared to $28,000 for the same period in 2024, primarily due to a non-cash loss from the change in fair value of warrants[139] Cash Flow - Net cash used by operating activities was $3,108,000 during the three-month period ended March 31, 2025, an increase of $551,000 from $2,557,000 in the same period of 2024[143] - Net cash used by investing activities was $673,000 for the three-month period ended March 31, 2025, with no cash flows from investing activities in the same period of 2024[144] - Net cash used by financing activities increased to $473,000 for the three-month period ended March 31, 2025, compared to $21,000 for the same period in 2024, primarily due to repayments of promissory notes[145] - As of March 31, 2025, the company's cash balance was $3,296,000[142] Future Outlook - The company expects net sales of Singing Machine products to decrease over the next 12 months due to tariffs on products manufactured in China, while revenue from the SemiCab business is expected to increase[132] - The company plans to invest in the SemiCab business to develop it into a significant revenue producer, focusing on technology research and development, marketing, and hiring qualified employees[125] - The company intends to continue relying on cash generated from operations, equity sales, and debt to fund operations and expansion efforts, including potential acquisitions[146] Acquisitions - The company completed the acquisition of the India component of the SemiCab business on May 2, 2025, following the acquisition of the U.S. component on July 3, 2024[126] Compliance - The company received a letter from Nasdaq on March 25, 2025, confirming compliance with the minimum bid price requirement of $1.00 per share for continued listing[151] Non-controlling Interest - Net loss attributable to non-controlling interest was $103,000 for the three-month period ended March 31, 2025, reflecting losses incurred by SemiCab allocated to SemiCab, Inc. through its 20% membership interest[140] One-time Charges - The company incurred a one-time, non-cash charge of $6,468,000 for the change in fair value of warrants related to a public offering completed on December 6, 2024[130]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-39796 Vivos Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) (Mark One) | Delaware | 81-3224056 | | --- | --- | | (State or other jurisdiction | (I.R.S. Employer | | of incorporation or organization) | Identification No.) | ☒ QUARTERLY REPORT PURSUA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to ___________________ Commission File Number: 001-33035 11250 Waples Mill Road, South Tower 210, Fairfax, Virginia 22030 (Address of principal execu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Jet.AI Inc. (Exact Name of Registrant As Specified In Its Charter) Delaware 93-2971741 (State or other jurisdiction of (I.R.S. Employer incorporatio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-40725 Jet.AI Inc. (Exact Name of Registrant As Specified In Its Charter) Delaware 93-2971741 (State or other jurisdictio ...